Strides Pharma Science share news and announcements
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Formerly Strides Shasun
Last close ₹1,014.80up ₹16.40 (1.64%)BSE ₹1,012.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹998.40.
52-week range of traded prices to 23 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,354 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 15.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 Jul 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 Jul 2026
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,12,38541.2% delivered
Strides Pharma Science analyst meets
70 filed, newest first. Page 1 of 2.
Aug 2026
Jul 2026
Jun 2026
8 Jun · Analysts
May 2026
28 May · Analysts
28 May · Analysts
28 May · Analysts
28 May · Analysts
28 May · Analysts
Feb 2026
4 Feb · Analysts
Jan 2026
Nov 2025
17 Nov · Analysts
Oct 2025
24 Oct · Analysts
Sep 2025
17 Sep · Analysts
Aug 2025
7 Aug · Analysts
Jul 2025
23 Jul · Analysts
May 2025
15 May · Analysts
Jan 2025
24 Jan · Analysts
Oct 2024
18 Oct · Analysts
Aug 2024
8 Aug · Analysts
Jul 2024
23 Jul · Analysts
May 2024
16 May · Analysts
Jan 2024
23 Jan · Analysts
Oct 2023
25 Oct · Analysts
24 Oct · Analysts
Sep 2023
20 Sep · Analysts
Jul 2023
26 Jul · Analysts
May 2023
23 May · Analysts
Jan 2023
23 Jan · Analysts
Nov 2022
Jul 2022
May 2022
Feb 2022
9 Feb · Analysts
Nov 2021
9 Nov · Analysts
Aug 2021
May 2021
Feb 2021
Oct 2020
Aug 2020